JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Madrigal Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

424.5 1.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

413

Massimo

424.77

Metriche Chiave

By Trading Economics

Entrata

31M

-42M

Vendite

76M

213M

EPS

-1.9

Margine di Profitto

-19.869

Dipendenti

528

EBITDA

31M

-39M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+21.75% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.9B

9.8B

Apertura precedente

422.56

Chiusura precedente

424.5

Notizie sul Sentiment di mercato

By Acuity

50%

50%

163 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

23 ott 2025, 23:51 UTC

Discorsi di Mercato

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 ott 2025, 23:37 UTC

Discorsi di Mercato

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 ott 2025, 22:58 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

23 ott 2025, 22:57 UTC

Discorsi di Mercato

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 ott 2025, 22:17 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 ott 2025, 21:41 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 ott 2025, 21:05 UTC

Utili

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 ott 2025, 20:35 UTC

Utili

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 ott 2025, 20:28 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 ott 2025, 20:15 UTC

Discorsi di Mercato
Utili

Global Commodities Roundup: Market Talk

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Adj EPS $1.71

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Sales $5.52B

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q EPS $1.67

23 ott 2025, 20:09 UTC

Utili

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 ott 2025, 20:07 UTC

Utili

Blackstone Looks to IPOs for Investment Exits -- Update

23 ott 2025, 20:05 UTC

Utili

Intel 3Q Gross Margin 38.2% >INTC

23 ott 2025, 20:04 UTC

Utili

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 ott 2025, 20:04 UTC

Utili

Intel: 4Q Guidance Excludes Altera >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Sees 4Q Adj EPS 8c >INTC

Confronto tra pari

Modifica del prezzo

Madrigal Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

21.75% in crescita

Previsioni per 12 mesi

Media 506.43 USD  21.75%

Alto 590 USD

Basso 266 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Madrigal Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

14

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

263.2 / 277.1Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

163 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat